RARE DISEASE DAY CONFERENCE 2018: Building on Research Excellence to Improve Patient Care Two-Day Interactive Conference
|
|
- Verity Gordon
- 6 years ago
- Views:
Transcription
1 March 21-22, 2018 DELTA OTTAWA CITY CENTRE, 101 Lyon Street Ottawa, Ontario How this Conference Will Make a Difference (for Rare Diseases in Canada) Day 1 (AM) In May 2015, the Canadian Organization for Rare Disorders, with multistakeholder collaboration, launched Canada s Rare Disease Strategy. It has become both the cornerstone and the touchstone for building Canada s Rare Disease Alliance, encompassing diagnosis and prevention, comprehensive expert treatment and care, community-based support, access to therapies, and research. This session will provide examples of excellence in rare disease spanning these areas, with a focus on application of genomics in diagnosis, models of multi-disciplinary/multistakeholder rare disease networks, Canadian discovery and development of drugs and devices, and support communities. Day 1 (PM) This multi-stakeholder session is a sobering reflection on real-world access to rare disease therapies (and other supports) in Canada. How well does Canada live up to good? Do patients get timely access to new (and promising) therapies through clinical trials, expedited approvals, early access programmes, patient-centred assessments, and individualized managed access programmes? And how good is the process? Are patients meaningfully engaged throughout the lifecycle? Are timelines respected? And are there procedures to assure transparency and accountability? AGENDA Day 1(March 21) 8:00 a.m. 8:45 a.m. 8:45 a.m. 9:00 a.m. 9:00 a.m. 9:15 a.m. Breakfast and Registration Welcome and Morning Objectives Canada s Rare Disease Strategy: Building on Today s Capabilities to Create Tomorrow s Opportunities Welcome and Morning Objectives Canada s Importance in in the World of Rare Diseases Paul Lévésque, Pfizer Inc. 9:15 a.m. 9:45 a.m. Accelerating rare disease diagnosis: Canada s excellence from research to clinical practice How did FORGE improve rare diagnosis through
2 genome (exome) sequencing? How has the Care4Rare Consortium contributed to translation of gene knowledge to treatment improvement? What can we hope from the next big collaboration: C4R-SOLVE Taila Hartley, CHEO Research Institute 9:45 a.m. 10:30 a.m. 10:30 a.m. 10:45 a.m. 10:45 a.m. 11:45 a.m. 11:45 a.m. 12:00 p.m. 12:00 p.m. 1:00 p.m. Rare Disease Centres of Expertise: what we are learning and what wll we need to sustain and expand? Neuromuscular Disease Network/SMA - (Craig Campbell, Children s Hospital, LHSC) Bone Disease Network - Cheryl Greenberg, Winnipeg Regional Health Authority Rhett Syndrome Community: Clinic, Registry, Research, Support Melissa Carter, Children s Hospital of Eastern Ontario Enhancing Canada s footprint in the development of therapies for rare diseases Discovery, adaptation, and targeting drugs for rare conditions - Daniel Drucker, Lunenfeld Tanenbaum Research Institute Novelion Therapeutics - Andrés Treviño, Novelion Therapeutics Medical devices to improve capabilities and support quality of life - Pamela Borges, B-TEMIA Inc How can we create caring communities that support and empower? Anna McCusker, Scleroderma Canada Wrap Up All Lunch
3 AGENDA Day 1 (PM ) Moderator: Bill Dempster, 3Sixty Public Affairs 1:00 p.m. 2:15 p.m. Bringing Rare Disease Drugs to Canada: Opportunities, Challenges, and More Challenges Current Status of Access to Rare Disease Drugs Through Canada s Approval Process Sherry O Quinn, MORSE Consulting How Patients Experience Access: (Patient Panel) Clinical Trials and Early Access of Orphan Drugs in Canada; SAP Regulatory Review: Expedited and Early-Stage Aprovals HTA Process for Rare Disease Drugs Funding through Private and Publc Plans Accessing Medical Devices for Rare Diseases 2:15 p.m. 2:30 p.m. 2:30 p.m. - 3:30 p.m. Current and Future Reality of Canadian Environment for Orphan Drugs Is Canada attracting clinical trials for rare diseases? How much support do researchers and innovative startups receive in Canada? Do companies feel Canada (still) needs Orphan Drug Regulatory Framework despite pathways to approval with existing legislation and regulations? Has review of rare disease drugs through the regular process for common drugs resulted in appropriate assessments and recommendations? Is a RDD pathway still needed? Does review through pcpa and public drug programs providing timely and appropriate access for patients with urgent, progressive, and life-threatening conditions to therapies that may have been approved with high uncertainty and high per patient costs? Is Canada bringing in alternative access solutions for drugs that do not fit the common paradigm?
4 How will proposed amendments to PMPRB affect rare disease drugs? Where are private plans now in coverage for rare diseases and what are the future directions? 3:30 p.m. 4:00 p.m. Rapprochement: Where are we now, where are we heading, and what do we need to be doing to assure timely patient access to rare disease drugs: What are we learning from the patient experience? What has improved over the past decade since the initial Fabry programme? What are we hoping for and what are we afraid of with reform taking place among all players in the drug lifecycle? What are the solutions for Canada? Comimg in Day 2. AGENDA Day 2 (AM) March 22 Health Canada Session 8:00 a.m. 8:30 a.m. Breakfast and Registration 8:30 a.m. 8:45 a.m. Welcome and Opening Remarks Durhane Wong-Rieger, President & CEO, CORD 8:45 a.m. 9:15 a.m. Regulatory Review of Drugs and Devices: R2D2 Megan Bettle, Director, Regulatory Innovation and Business Operations, BGTD, Health Canada 9:15 a.m. 9:45 a.m. Regulatory Review of Drugs for Rare Diseases: Updates and Ongoing Activities Fiona Frappier, PhD, Senior Policy Analyst, Health Canada
5 9:45 a.m. 10:15 a.m. 10:15 a.m. 10:30 a.m. Panel Q & A Megan Bettle Fiona Frappier Cathy Parker, Director General, Biologics and Genetic Therapies Directorate, Health Canada 10:30 a.m. 11:50 a.m. Panel Discussion on R2D2: Collaboration Amongst Health Portfolio Partners Doug Clark, PMPRB Brian O Rourke, CADTH Luc Boileau, INESSS Imran Ali, pcpa Scott Doidge, DG, Department of Indigenous Services Suzanne McGurn, Ontario Drug Programme, MOHLTC Pamela Fralick, Innovative Medicines Canada Megan Bettle, Health Canada Cathy Parker, Health Canada 11:50 a.m. 12:00 p.m. 12:00 pm 1:00 pm Wrap up Cathy Parker, Director General, Biologics and Genetic Therapies Directorate, Health Canada Lunch
6 AGENDA Day 2 (PM ) University of Alberta PRISM and Integrative Health Institute Workshop: Systems Thinking to Design Managed Access that Works Moderators: Dev Menon, Tania Stafinski, University of Alberta 1:00 p.m. 2:15 p.m. What have we learned from successful Canadian experiences with various forms of managed access to rare and specialty drugs? What are best international examples of access to orphan drugs, including early and expedited access? 2:15 p.m. 2:30 p.m. 2:30 p.m. - 3:30 p.m. How can we better engage patients and caregivers to develop relevant outcome measures and to participate as partners in managed access? What are system process requirements and contribution of all stakeholders to assure success of managed access to reduce risk and uncertainty while expediting access to patients with urgent and chronic needs? 3:30 p.m. 4:00 p.m. Wrap up and Closing Remarks Detailed AGENDA in development
Rare Disease Day 2018
Delta Ottawa City Centre, 101 Lyon Street, Ottawa, Ontario Building on Research Excellence to Improve Patient Care AGENDA March 21, 2018 8:00 a.m. 8:45 a.m. Breakfast and Registration - Ballroom A/B 8:45
More informationRecommendations for Implementing a World- Class State- of- the- Art Canadian Newborn Screening Programme
Recommendations for Implementing a World- Class State- of- the- Art Canadian Newborn Screening Programme Submitted by: Canadian Organization for Rare Disorders Durhane Wong- Rieger, PhD, President & CEO
More informationFrom HTA recommendation to adoption at scale
D E V E L O P I N G T A L E N T G R O W I N G V E N T U R E S O P E N I N G M A R K E T S From HTA recommendation to adoption at scale Zayna Khayat, Ph.D. Sr. Advisor, Health System Innovation Lead, Director,
More informationSubmission to Canada s Fundamental Science Review Executive Summary and Recommendations
Submission to Canada s Fundamental Science Review Executive Summary and Recommendations 1 Executive Summary The federal government s review of fundamental research funding presents an important opportunity
More informationEuropean Reference Networks (ERN) Guide for patient advocates
European Reference Networks (ERN) Guide for patient advocates 1. European Reference Networks (page 1-3) a. What is an ERN? b. Who is a member of an ERN? c. Affiliated/ collaborative centres d. The IT platform
More informationCONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION
CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION November 2016 ABOUT CORD The Canadian Organization for Rare Disorders (CORD) provides a strong common voice to advocate for health policy and a healthcare
More informationTomorrow s Health Care Today
Tomorrow s Health Care Today Ottawa Hospital Research Institute Strategic Directions 2011-2014 Message from the CEO I came to Ottawa in 2007 because I recognized the unique opportunity that existed for
More informationConfronting the Challenges of Rare Disease:
Confronting the Challenges of Rare Disease: SOLUTIONS ACROSS THE ENTIRE PRODUCT LIFE CYCLE The Orphan Drug Act of 1983 brought increased awareness to the need for new treatments for rare disease patients
More informationConsensus Statement on the Mental Health of Emerging Adults: Making Transitions a Priority in Canada. Executive Summary
Consensus Statement on the Mental Health of Emerging Adults: Making Transitions a Priority in Canada Executive Summary Ce document est disponible en français. This document is available at www.mentalhealthcommission.ca
More informationTransforming Engaging Integrating. Conference Overview WEDNESDAY JUNE 14, 2017 THURSDAY JUNE 15, Christine Elliott, Patient Ombudsman
11:00 AM 7:00 PM Delegate Registration 7:00 PM 9:00 PM Opening Reception WEDNESDAY JUNE 14, 2017 THURSDAY JUNE 15, 2017 8:00 AM 10:00 AM Opening Plenary until 8:45 AM then 8:45 AM 9:45 AM Keynote Susan
More informationHealthy Canada. HEALTHY BRAINS ACROSS THE LIFESPAN MARCH 2, 2016 TORONTO CONFERENCE AGENDA. #CBoCHealth
CONFERENCE AGENDA MARCH 2, 2016 TORONTO HEALTHY BRAINS ACROSS THE LIFESPAN Healthy Canada. Alex Munter President and Chief Executive Officer, The Children s Hospital of Eastern Ontario Edward Mantler Vice-President,
More informationOTTAWA QUALITY & PATIENT SAFETY CONFERENCE
2018 OTTAWA QUALITY & PATIENT SAFETY CONFERENCE TUESDAY OCTOBER 30 TH OVERVIEW The Ottawa Hospital, the Bruyère Research Institute, the QUILT Network (QUality for Individuals who require Long-Term support),
More information21 March NHS Providers ON THE DAY BRIEFING Page 1
21 March 2018 NHS Providers ON THE DAY BRIEFING Page 1 2016-17 (Revised) 2017-18 (Revised) 2018-19 2019-20 (Indicative budget) 2020-21 (Indicative budget) Total revenue budget ( m) 106,528 110,002 114,269
More informationCollaborating with patients: learning from psoriasis and other diseases
Collaborating with patients: learning from psoriasis and other diseases Marilyn Metcalf, PhD Sr. Dir., Benefit Risk Evaluation Chief Medical Office EveryLife Foundation for Rare Diseases September 15,
More informationSMA Clinical Care Center Network / Clinical Data Registry & Clinical Trials Site Readiness for SMA. March 21, 2018
SMA Clinical Care Center Network / Clinical Data Registry & Clinical Trials Site Readiness for SMA March 21, 2018 SMA Clinical Care Center Network & Clinical Data Registry Mary Schroth, MD Chief Medical
More informationForward-Looking Statements
Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks,
More informationEuropean Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
More informationMoving Boldly into Our Future
Moving Boldly into Our Future Strategic Plan 2017 We have crafted a thoughtful and inspiring blueprint for the future. A message from Dr. Jeff Sperring, CEO At Seattle Children s, we are privileged to
More informationANNUAL CCSPA GOVERNMENT INTERFACE 2013 Marriott Ottawa Hotel Fostering Successful Partnerships in the New Fiscal Reality AGENDA
TUESDAY, APRIL 23, 2013 BOARD MEETING AGENDA 9:30 a.m. 11:45 a.m. CCSPA Board of Directors (includes breakfast and lunch) (CCSPA Board members only) Location: ALBERT SALON MEETING 9:30 a.m. 11:45 a.m.
More information21st Annual Practical Review for the Clinician: Pediatric Allergy, Immunology and Infectious Diseases
21st Annual Practical Review for the Clinician: Pediatric Allergy, Immunology and Infectious Diseases Friday, Nov. 10, 2017 Ruth and Tristram Colket, Jr. Translational Research Building Learn more: chop.cloud-cme.com
More informationMember webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016
Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016 1 What a European Reference Network is for us? Highly specialised healthcare networks meeting the needs
More informationProposed Regulated Health Professions General Regulation (The Regulated Health Professions Act) Consultation Draft
TABLE OF CONTENTS Section 1 Definitions 2 Defined terms for the Act and regulations DEFINITIONS EXEMPTIONS RESERVED ACTS 3 Acupuncture 4 Male circumcision 5 Transplant surgeons 6 Registered technologists
More informationMasterclass NieuweZorg 3.0 De farmaceutische sector op Europees niveau. Author: Elizabeth Kuiper* Date: Maart 2016 * Presentation.
Masterclass NieuweZorg 3.0 De farmaceutische sector op Europees niveau Author: Elizabeth Kuiper* Date: Maart 2016 * Presentation www.efpia.eu About us Most businesses think that product is the most important
More informationBANAC 6 th ANNUAL ABORIGINAL HEALTH FORUM
CHIEFS OF ONTARIO BANAC 6 th ANNUAL ABORIGINAL HEALTH FORUM The Need for Transformative Change in the Health System Blue Mountain Inn March 29, 2017 Who is COO? (Chiefs of Ontario) Combined political/technical
More informationACHIEVING PATIENT-CENTRED COLLABORATIVE CARE (2008)
CMA POLICY ACHIEVING PATIENT-CENTRED COLLABORATIVE CARE (2008) The Canadian Medical Association (CMA) recognizes that collaborative care is a desired and necessary part of health care delivery in Canada
More informationNumber of attendees:limited space is available for 70 trainees and 20 faculty members.
Title: Technology Transfer and Commercialization (TTC) Workshop: Career Paths and Research Funding Opportunities Dates: July 30 & 31, 2015 Sponsored by: Network for Canadian Oral Health Research(NCOHR)
More informationReal World Evidence in Europe
Real World Evidence in Europe Jessamy Baird, RWE Director Madrid, 20 th October 2014. BEFORE I BEGIN; DISCLAIMERS: Dual perspective: Pharmaceutical: I work for Lilly, but this presentation represents my
More information2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program
2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program Release Date: November 3, 2017 Application Due Date: February
More information2017 INNOVATION FUND. Guidelines for Multidisciplinary Assessment Committees
2017 INNOVATION FUND Guidelines for Multidisciplinary Assessment Committees June 2016 TABLE OF CONTENTS MANDATE OF THE CANADA FOUNDATION FOR INNOVATION... 3 2017 INNOVATION FUND COMPETITION... 3 THE CFI
More informationEuropean Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications
European Reference Networks Guidance on the recognition of Healthcare Providers and UK Oversight of Applications NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients
More informationRESOLUTIONS ADOPTED (confirmed) 148th Annual Meeting of the Canadian Medical Association Aug , 2015 Halifax, NS
Governance 1. The Canadian Medical Association (CMA) approves the Canadian Society for Vascular Surgery s application for CMA affiliate status. (BD 1-1) 2. The Canadian Medical Association (CMA) approves
More informationIAMRARE Natural History Study (NHS) Patient Registry
IAMRARE Natural History Study (NHS) Patient Registry 1 in 10 Americans has a rare disease. 2 About NORD The National Organization for Rare Disorders (NORD), established in 1983, is the leading advocacy
More informationNotice. Update: Increased Scope of Submissions being accepted in Electronic Common Technical Document (ectd) electronic-only filing format
Notice September 30, 2011 Our file number: 11-117819-54 Update: Increased Scope of Submissions being accepted in Electronic Common Technical Document (ectd) electronic-only filing format Health Canada
More informationThank you for joining us today!
Thank you for joining us today! Please dial 1.800.732.6179 now to connect to the audio for this webinar. To show/hide the control panel click the double arrows. 1 Emergency Room Overcrowding A multi-dimensional
More informationRemarks by Russell Williams President Canada s Research-Based Pharmaceutical Companies Rx&D. Canadian Clinical Trials Summit
Remarks by Russell Williams President Canada s Research-Based Pharmaceutical Companies Rx&D Canadian Clinical Trials Summit September 15, 2011 Ottawa, Ontario Check against delivery Thank you Wayne, Today
More informationIBM Watson Health Empowering Heroes. Transforming Health.
35 th Annual J.P. Morgan Healthcare Conference January 11, 2017 IBM Watson Health Empowering Heroes. Transforming Health. Deborah DiSanzo General Manager, IBM Watson Health Forward Looking Statements Certain
More informationSASKATCHEWAN ASSOCIATIO. RN Specialty Practices: RN Guidelines
SASKATCHEWAN ASSOCIATIO N RN Specialty Practices: RN Guidelines July 2016 2016, Saskatchewan Registered Nurses Association 2066 Retallack Street Regina, SK S4T 7X5 Phone: (306) 359-4200 (Regina) Toll Free:
More informationNational Guidelines for a Comprehensive Service System to Support Family Caregivers of Adults with Mental Health Problems and Illnesses SUMMARY
National Guidelines for a Comprehensive Service System to Support Family Caregivers of Adults with Mental Health Problems and Illnesses SUMMARY Prepared by Penny MacCourt, MSW, PhD and the Family Caregivers
More informationExpanded Access Programs 2016
REGISTER BY DECEMBER 11, 2015 & SAVE $300! Expanded Access Programs 2016 U.S. and Global Models for Stakeholder Collaboration, Program Design and Supply Equity FEBRUARY 23-24, 2016 DOUBLETREE BY HILTON
More informationEUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)
EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) 31 January 2013 1 EUCERD RECOMMENDATIONS ON RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) INTRODUCTION 1. BACKGROUND TO
More informationTransforming Health Care Through Digital Innovations
Transforming Health Care Through Digital Innovations With Digital Health Week occurring on November 13-19, the Centre for the Future of Health will be focusing on the value of and opportunities with digital
More informationMONDAY, MAY 28TH, 2018 (Pre-Conference)
MONDAY, MAY 28TH, 2018 (Pre-Conference) 12:30pm to 3:30pm SALON LASALLE 1:00PM to 5:00pm F Why Aren t Health Leaders Leading Health Research Agendas: Analysis and Action This workshop will focus on a Pan
More informationNavigating Health System Silos Promoting Innovative Policies and Best Practices. Monday, October 17, 2016 MaRS Discovery District, Toronto
Navigating Health System Silos Promoting Innovative Policies and Best Practices Monday, October 17, 2016 MaRS Discovery District, Toronto Meet the Panel Moderator: Janet Davidson (former Deputy Minister
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationRobot-Assisted Surgeries A Project for CADTH, a Decision for Jurisdictions
Robot-Assisted Surgeries A Project for CADTH, a Decision for Jurisdictions 2012 CADTH Symposium Panel Discussion Dr. Janice Mann Mr. Michel Boucher Dr. Nina Buscemi We NEED this! What is a Surgical Robot?
More informationImproving the health of all Canadians: A vision for the future
Improving the health of all Canadians: A vision for the future The CMA s platform on the 2017 federal/provincial/territorial health accord Table of contents Why Canada needs a new health accord... 3 Improving
More informationCASE-BY-CASE REVIEW PROGRAM (CBCRP) CASE-BY-CASE REVIEW POLICY FOR CANCER DRUGS
CASE-BY-CASE REVIEW PROGRAM (CBCRP) CASE-BY-CASE REVIEW POLICY FOR CANCER DRUGS Version: 3.0 Effective Date: October 2013 Replaces Policy: Case-by-Case Review Policy for Cancer Drugs, November 8, 2011
More informationCultural Competence and Cultural Safety: A Knowledge Translation Symposium
Cultural Competence and Cultural Safety: A Knowledge Translation Symposium Courtyard by Marriott Downtown Toronto Hotel Monday, March 19 th, 2012 and Tuesday, March 20 th,2012 Welcome Bienvenue Special
More informationInterim Results: Rapid Cycle Evaluation. Anna Greenberg, Director, Transformation Secretariat, MOHLTC
Interim Results: Rapid Cycle Evaluation Anna Greenberg, Director, Transformation Secretariat, MOHLTC Current Evaluation Activities Rapid Cycle Evaluation Baseline conditions Early implementation results
More informationCPC+ CHANGE PACKAGE January 2017
CPC+ CHANGE PACKAGE January 2017 Table of Contents CPC+ DRIVER DIAGRAM... 3 CPC+ CHANGE PACKAGE... 4 DRIVER 1: Five Comprehensive Primary Care Functions... 4 FUNCTION 1: Access and Continuity... 4 FUNCTION
More informationA REPORT OF THE ONTARIO CITIZENS COUNCIL
A REPORT OF THE ONTARIO CITIZENS COUNCIL DRUGS FOR RARE DISEASES Submitted to: Suzanne McGurn Executive Officer and Assistant Deputy Minister Ontario Public Drug Programs Ontario Ministry of Health and
More informationCulture and Diversity in the Armed Forces
Culture and Diversity in the Armed Forces Co-hosted by CIMVHR, CAF and CIDP AGENDA - *Please note that the agenda is subject to change 08:00AM Registration 08:30 Welcome Dr. Stéphanie Bélanger, Interim
More information3/3/2014. Advance Practice Nursing-a Varied and Unique Role in a Comprehensive Breast Program. Lecture/Session. Health Care Reform
Advance Practice Nursing-a Varied and Unique Role in a Comprehensive Breast Program Colleen Johnson, R.N.N.P., CBPN IC Carondelet Health System Lecture/Session RT s #43 No Disclosures Health Care Reform
More informationStrategy for Partnerships And Innovation
Strategy for Partnerships And Innovation University of Manitoba, February 3, 2014 My Goals Today Discuss Interaction, Engage, Engage Plus grants Answer questions Interaction Grants Allow university researchers
More informationRare Disease Registries
Rare Disease Registries Dr Marcus Klein, Senior Director, Regional Medical Officer J-APAC Anne Fabry Disease Denmark Discussion Topics Evolution and increasing role of Observational Research Genzyme s
More informationFocus on your future. Take your business to new heights by always thinking and looking ahead.
5Insights for entrepreneurs Focus on your future Take your business to new heights by always thinking and looking ahead. Entrepreneurs are the engine that powers Canada s economy. The so-called small business
More informationProfessional Biography
'MIND THE GAP!': HOW SHOULD WE MANAGE THE DIFFERENCE BETWEEN REGULATORY AND REIMBURSEMENT EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES? Nneka Onwudiwe PharmD PhD MBA PRO/PE Regulatory Reviewer Professional
More informationObjectives. Models of Integrated Behavioral Health Care 9/23/2015
Models of Integrated Behavioral Health Care Carlton D. Craig, Ph.D. Vernon R. Wiehe Endowed Professor in Family Violence University of Kentucky College of Social Work Carlton.craig@uky.edu (859)-257-6657
More informationOur Commitment to Deliver our Science to Patients
to Deliver our Science to Patients 1 In an uncertain world, science is a force for good. It is easy to overlook its transformative power and benefits to society. Pascal Soriot, CEO AstraZeneca We Put Patients
More informationPresenter Biographies
Master Class Implementing Integrated Care By: Dr. Walter Wodchis, Associate Professor, Institute of Health Policy, Management and Evaluation at the University of Toronto Dr. Ross Baker, Professor, Institute
More informationImproving Transitions from Child to Adult Care
Improving Transitions from Child to Adult Care October 19, 2016 @cfhi_fcass Please introduce yourself and your organization name 4 Let s Tweet Together: Join the conversation on Twitter! @CFHI_FCASS @CAPHC
More informationAnnual Report 2016/2017
Annual Report 2016/2017 Positioning Ontario as the preferred place for global clinical trials CLINICAL TRIALS ONTARIO OUR Vision OUR Mission To make Ontario a preferred location for global clinical trials
More informationOverview of the Congressionally Directed Medical
US Army Medical Research and Materiel Command (USAMRMC) Overview of the Congressionally Directed Medical Research Programs (CDMRP) Presented by Melissa A. Forsythe, Ph.D. Colonel, U.S. Army (Retired) Program
More informationClinical Research Network Kent, Surrey and Sussex. Specialty Group Clinical Lead
Clinical Research Network Kent, Surrey and Sussex Specialty Group Clinical Lead The National Institute for Health Research (NIHR) is funded through the Department of Health to improve the health and wealth
More informationCANADIAN SYRINGOMYELIA AND CHIARI MALFORMATION CONFERENCE Sheraton Parkway Toronto North Hotel November 11 th, 12 th & 13 th,2004
CANADIAN SYRINGOMYELIA AND CHIARI MALFORMATION CONFERENCE Sheraton Parkway Toronto North Hotel November 11 th, 12 th & 13 th,2004 WHY YOU SHOULD ATTEND Meet with others who have Syringomyelia and Chiari
More informationCompetitors' Package. Jan 18-21,
Competitors' Package Jan 18-21, 2018 www.theqec.com TABLE OF CONTENTS Who We Are... 1 Why Compete... 2 Past Competitors... 3 Competition Structure & Prize... 4 About The Rounds... 5 Application Criteria...
More information2018 Western Regional Angel Summit
Host Partners 2018 Western Regional Angel Summit Connecting the Innovation Ecosystem in Western Canada Victoria Ocean Pointe Resort Victoria, BC February 21-23, 2018 PARTNERSHIP OPPORTUNITIES Connecting
More informationHospital and Other Healthcare Facilities
Hospital and Other Healthcare Facilities Council Progress Report December 2015 Judy Chong, RPh, BScPhm Manager, Hospital and Other Healthcare Facilities Agenda Background Drug Preparation Premises (DPPs)
More informationDNAnexus Connect 2017 Agenda Kimpton Marlowe Hotel Cambridge, MA
DNAnexus Connect 2017 Agenda Kimpton Marlowe Hotel Cambridge, MA Thursday, October 5 th At-A-Glance 8:30 AM 9:00 AM Breakfast and Registration 9:00 AM 10:30 AM Presentations 10:30 AM 11:00 AM 11:00 AM
More informationNEXT GEN HEALTH CARE: INTEGRATING CHILDREN S BEHAVIORAL HEALTH IN 2017 AND BEYOND
NEXT GEN HEALTH CARE: INTEGRATING CHILDREN S BEHAVIORAL HEALTH IN 2017 AND BEYOND BALTIMORE, MD JUNE 14 15, 2017 NACBH s mission is to advance the field of children s behavioral health by engaging talented
More informationPartnership Assessment Tool for Health: Bridging Health Care & Community-Based Human Services
Nonprofit Finance Fund Partnership Assessment Tool for Health: Bridging Health Care & Community-Based Human Services Presentation to Center for Care Innovations Safety Net Innovations Network May 3, 2018
More informationNIHR Funding Opportunities
NIHR Funding Opportunities David King Newcastle 12 th May, 2008 Consultation 2005 New Government Strategy 2006 Best for Best Health Vision To create a health research system in which the NHS: supports
More informationPatient and Citizen Engagement in HTA Decision Making. E4 Panel session, CADTH Symposium, May7th, 2013
Patient and Citizen Engagement in HTA Decision Making E4 Panel session, CADTH Symposium, May7th, 2013 1 Agenda Moderation o Paul Oh Patient perspective o Durhane Wong-Reiger Citizen perspective o Janet
More informationCross-Border Enrollment of Rare Disease Patients
WHITE PAPER Cross-Border Enrollment of Rare Disease Patients Considerations for Planning & Conducting Global Rare Disease Clinical Trials Authors: AMY RAYMOND, PHD, PMP Clinical Scientist Scientific Affairs,
More informationThe Ottawa Hospital Strategy
The Ottawa Hospital Strategy 2015 2020 1 We are pleased to present you with The Ottawa Hospital 2015-2020 strategy, which builds upon the momentum of our successes to date in providing high-quality, compassionate
More informationExecutive Summary. Prescription for Holistic Care. Improving Access to Medications through Ontario s Mental Health and Addictions Strategy
Executive Summary Prescription for Holistic Care Improving Access to Medications through Ontario s Mental Health and Addictions Strategy JUNE, 2015 Acknowledgements The Schizophrenia Society of Ontario
More informationReview of the 10-Year Plan to Strengthen Health Care
Review of the 10-Year Plan to Strengthen Health Care House of Commons Standing Committee on Health Dr. Marlene Smadu, President, Canadian Nurses Association Ottawa, Ontario May 27, 2008 INTRODUCTION The
More informationNorth Zone, Alberta Health Services, Alberta
North Zone, Alberta Health Services, Alberta NRoR Shelly Pusch Chief Zone Officer, North Zone Shelly Pusch has worked in health for almost 30 years and has a devoted interest in rural Alberta. She is currently
More informationOfficial Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10
Official Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10 Presented by 26-27 September, 2011 Government Conference Centre 2 Rideau Street (opposite Chateau Laurier) Ottawa, ON K1N 8X5
More informationAssignment Of Client Care: Guidelines for Registered Nurses
Assignment Of Client Care: Guidelines for Registered Nurses May 2014 Approved by the College and Association of Registered Nurses of Alberta (CARNA) Permission to reproduce this document is granted; please
More informationMinister s Task Force on the Prevention of the Sexual Abuse of Patients and the Regulated Health Professions Act, 1991 (Task Force)
Minister s Task Force on the Prevention of the Sexual Abuse of Patients and the Regulated Health Professions Act, 1991 (Task Force) Tim Lenartowych, RN, BScN, LLM Director of Nursing and Health Policy
More informationREGISTERED NURSES AND NURSE PRACTITIONERS - AIDING IN MEDICAL ASSISTANCE IN DYING
2016 REGISTERED NURSES AND NURSE PRACTITIONERS - AIDING IN MEDICAL ASSISTANCE IN DYING This document was approved by the ARNNL Council in July 2016. Registered Nurses and Nurse Practitioners - Aiding in
More informationFirst Nations Child and Family Caring Society of Canada. - and - Assembly of First Nations. - and - Canadian Human Rights Commission.
Canadian Human Rights Tribunal Tribunal canadien des droits de la personne Citation: 2017 CHRT 35 Date: November 2, 2017 File No.: T1340/7008 Between: First Nations Child and Family Caring Society of Canada
More informationQuality and Value in Home Care Building a Shared Vision of Value and Sustainability in Ontario s Home Care Sector
Quality and Value in Home Care Building a Shared Vision of Value and Sustainability in Ontario s Home Care Sector CHCA Conference Presentation October 30, 2013 Jacqueline Redmond (CEO, South East CCAC)
More informationINNOVATION ECOSYSTEM ONTARIO S
ONTARIO S INNOVATION ECOSYSTEM If your business is driven by innovation, then Ontario is the place to take your ideas from the drawing board to the market. Our innovation ecosystem is the perfect environment
More informationIMPROVED PATIENT OUTCOMES AND FINANCIAL PERFORMANCE THE VALUE OF INTEGRATED OUTSOURCED SERVICES SUPPORTING RARE DISEASE PHARMACEUTICAL COMPANIES.
IMPROVED PATIENT OUTCOMES AND FINANCIAL PERFORMANCE THE VALUE OF INTEGRATED OUTSOURCED SERVICES SUPPORTING RARE DISEASE PHARMACEUTICAL COMPANIES. By 2020, the global cost of orphan drugs is expected to
More informationENGAGE. ALIGN. INFLUENCE:
ENGAGE. ALIGN. INFLUENCE: Implementation & Evaluation Friday, April 20 th, 2018 The Doctors House - 21 Nashville Road, Kleinburg, ON Agenda 08:00-08:30 Registration 08:30-08:40 Welcome Valerie Winberg,
More information2 Annual Clinical Trial Methods & Design Workshop for Junior Faculty
The University of Texas MD Anderson Cancer Center nd 2 Annual Clinical Trial Methods & Design Workshop for Junior Faculty May 7-9, 2015 The Houstonian Hotel, 111 N. Post Oak Ln. Houston, Texas Sponsored
More informationCommunity Oncology Town Hall. Moderator John Cox, DO, FASCO
Community Oncology Town Hall Moderator John Cox, DO, FASCO Rough Waters for Practices Economic pressures Political turbulence General disruption across medicine Sequestration ICD-10 PQRS, Meaningful Use
More informationExecutive Summary. Leadership Toolkit for Redefining the H: Engaging Trustees and Communities
Executive Summary Leadership Toolkit for Redefining the H: Engaging Trustees and Communities Report produced by the AHA Committee on Research and Committee on Performance Improvement 2015 Executive Summary
More informationHHS DRAFT Strategic Plan FY AcademyHealth Comments Submitted
HHS DRAFT Strategic Plan FY 2018 2022 AcademyHealth Comments Submitted 10.26.17 AcademyHealth was pleased to have an opportunity to comment on the U.S. Department of Health and Human Services (HHS) draft
More informationOn The Path to a Cure: From Diagnosis to Chronic Disease Management. Brief to the Senate Committee on Social Affairs, Science and Technology
250 Bloor Street East, Suite 1000 Toronto, Ontario M4W 3P9 Telephone: (416) 922-6065 Facsimile: (416) 922-7538 On The Path to a Cure: From Diagnosis to Chronic Disease Management Brief to the Senate Committee
More informationNational Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health
National Plans for Rare Diseases The French plan 2005-2008 2008 Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health Political Context Public Health Law of 9 August 2004 100
More informationAzrieli Foundation - Brain Canada Early-Career Capacity Building Grants Request for Applications (RFA)
Azrieli Foundation - Brain Canada Early-Career Capacity Building Grants Request for Applications (RFA) About the Azrieli Foundation For almost 30 years, the Azrieli Foundation has funded institutions as
More informationEconomic and Social Council
United Nations E/CN.3/2015/20 Economic and Social Council Distr.: General 8 December 2014 Original: English Statistical Commission Forty-sixth session 3-6 March 2015 Item 4 (a) of the provisional agenda*
More informationAlberta Breathes: Proposed Standards for Respiratory Health of Albertans
Alberta Breathes: Proposed Standards for Respiratory Health of Albertans The concept of Alberta Breathes and these standards was developed in consultation with over 150 health professionals and stakeholders
More informationPatient-Centred Decision Making with MCDA: Should We Be Trying to Quantify the Patient Voice for Use in HTA?
Patient-Centred Decision Making with MCDA: Should We Be Trying to Quantify the Patient Voice for Use in HTA? ISPOR 2016, Vienna, 31 October 2016 Prof. Dr. Peter Kolominsky-Rabas, M.D.; M.B.A. Interdisciplinary
More informationImplementation Plan for the UK Strategy for Rare Diseases
Implementation Plan for the UK Strategy for Rare Diseases NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning
More informationThe Role of the Agency for Healthcare Research and Quality (AHRQ) in the US Drug Safety System
The Role of the Agency for Healthcare Research and Quality (AHRQ) in the US Drug Safety System Scott R. Smith, MSPH, PhD Center for Outcomes & Evidence Agency for Healthcare Research & Quality July 20,
More informationGenomic Applications Partnership Program (GAPP) Investment strategy and exceptions to Genome Canada s Guidelines for Funding
Genomic Applications Partnership Program (GAPP) Investment strategy and exceptions to Genome Canada s Guidelines for Funding December 1, 2017 1 Contents 1. GAPP Overview... 3 2. GAPP Objectives... 4 3.
More information